(CIDRAP News) Influenza activity persists at medium to high levels in most European Union countries but is showing signs of decreasing, according to the latest report from the European Centre for Disease Prevention and Control (ECDC).
(CIDRAP News) The European Medicine Agency (EMA) said today it is not clear if there is any link between narcolepsy cases and the Pandemrix vaccine for 2009 H1N1 influenza, and it will take 3 to 6 months to investigate the possibility fully.
Norway OKs OTC antiviral salesTo ease response to the H1N1 pandemic, Norway is allowing over-the-counter sales of oseltamivir (Tamiflu) and zanamivir (Relenza), the Associated Press (AP) reported. The new policy starts tomorrow and is in effect until the middle of 2010. Norway has ordered 9.4 million doses of vaccine, but the manufacturer has reportedly not produced enough to meet demand.